Publications
5674 Results
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr LBA3); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), oral, plenary
- Year
- 2020
- Research Committee(s)
- Myeloma
- Study Number(s)
- CTSU/E1A11
Carfilzomib, lenalidomide and dexamethasone (KRd) versus Bortezomib, lenalidomide and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase 3 trial
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr LBA2); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), oral, plenary
- Year
- 2020
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/E2108
A randomized Phase Ill trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo Stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108)
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr e22078); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), publication only
- Year
- 2020
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609
Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 1118, IIIC, Mla, Mlb) randomized to low- or high-dose adjuvant lpilimumab (ipi) versus highdose interferon alfa-2b {HDI): Health-related quality of life {HRQL) analysis of ECOG-ACRIN E1609
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr e22090); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), publication only
- Year
- 2020
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609
Unknown primary tumor high-risk melanoma as a unique patient population with distinct prognosis in the adjuvant setting: An ECOG-ACRIN E1609 study analysis
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr TPS3154); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
- Study Number(s)
- CTSU/A151804
ALLIANCE A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 8038); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0016, S0801
Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 11562); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
A Randomized Phase II Study of MLN0128 (M) vs. Pazopanib (P) in Pts with Advanced Sarcoma (Alliance A091304)
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr e16076); American Society of Clinical Oncology 2020 Annual Meeting, publication only
- Year
- 2020
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405, N9741
Rural and urban disparities based on zip code of residence: Analyses of 834 and 2159 patients in N9741 and CALGB 80405 trials respectively.
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 4086); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 10059); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1320